Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Similar documents
03/14/17. II. Initial early intensive-level behavioral and developmental therapy must have both of the following: A and B

01/26/17. Replaces Effective Policy Dated: Autism Spectrum Disorders in Children: Assessment 01/19/16 and Evaluation Reference #: MP/A005 Page 1 of 4

Department of Origin: Integrated Healthcare Services. Approved by: Chief Medical Officer Department(s) Affected: Date approved: 01/10/17

01/10/17. Replaces Effective Policy Dated: Amino Acid Based Elemental Formula (AABF) 09/28/15 Reference #: MP/A003 Page: 1 of 3

PURPOSE: The intent of this policy is to provide guidelines for coverage of dental procedures under the medical benefit.

03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and

06/13/17. A. Completed a comprehensive diabetes education program within the past two years; and

09/12/17. I. Electrical Bone Growth Stimulator (invasive, semi-invasive, or non-invasive) any of the following: A-C

FYI ONLY Generic Name. Generics available. zoledronic acid N/A

No An act relating to health insurance coverage for early childhood developmental disorders, including autism spectrum disorders. (S.

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or

Smile SM Value 50/1500/No Ortho/MAC

PANCREATIC ISLET TRANSPLANT

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

Smile SM Deluxe Gold 50/1500/Ortho/U85

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

Smile SM Plus 50/1500/Ortho/MAC

12/13/16. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B

Pediatric Dental and Vision

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

12/12/17. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B

LARTRUVO (olaratumab)

IMMUNE CELL FUNCTION ASSAY

Calendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays. n/a Office visit $5 per visit

Santa Clara Family Health Plan Cal MediConnect Plan (Medicare-Medicaid Plan) 2017 Drug List

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

06/12/18. [Note: When orthognathic surgery is not a covered benefit, it is non-covered for any diagnosis, including sleep apnea.]

2018 Preventive Schedule

GENETIC TESTING FOR TAMOXIFEN TREATMENT

Calendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

APOKYN (apomorphine hydrochloride)

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

Tusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible

Applied Behavior Analysis for Autism Spectrum Disorders

ALPHA1-PROTEINASE INHIBITORS

Approval of a drug under this criteria document does not ensure full coverage of the drug.

ENTYVIO (vedolizumab)

03/13/18. PURPOSE: The intent of this criteria document is to ensure services are medically necessary.

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

PARSABIV (etelcalcetide)

Tusculum College. Benefit Summary Option/Quote: 2. 30% after Deductible. $35 Copay. 30% after Deductible

POLICY AND PROCEDURE

TREATMENTS FOR GAUCHER DISEASE

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether

STELARA (ustekinumab)

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

BLINCYTO (blinatumomab)

Dental Options 2018 BALTIMORE CITY PUBLIC SCHOOLS

MYLOTARG (gemtuzumab ozogamicin)

NEW YORK STATE MEDICAID PROGRAM REHABILITATION SERVICES POLICY GUIDELINES

MEDICAL POLICY Children's Intensive Behavioral Service/ Applied Behavioral Analysis (ABA)

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

ORAL IMPLANT PROCEDURES

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

Speech Therapy. 4. Therapy is used to achieve significant, functional improvement through specific diagnosisrelated

CIMZIA (certolizumab pegol)

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

BRINEURA (cerliponase alfa)

NUTRIENT OR NUTRITIONAL PANEL TESTING

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

MEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS

NEGATIVE PRESSURE WOUND THERAPY

H.P. ACTHAR GEL (repository corticotropin injection)

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

GENETIC TESTING FOR NEUROFIBROMATOSIS

TYSABRI FOR CROHN S DISEASE

DEEP BRAIN STIMULATION

PERCUTANEOUS BALLOON KYPHOPLASTY, RADIOFREQUENCY KYPHOPLASTY, AND MECHANICAL VERTEBRAL AUGMENTATION

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED MARCH 14, 2016

GENETIC TESTING FOR HEREDITARY HEARING LOSS

Medical Policy Original Effective Date: Revised Date: Page 1 of 6

2017 Preventive Schedule

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Small Group. SG_Ren_

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

KYMRIAH (tisagenlecleucel)

INTRAVITREAL IMPLANTS

MEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

Transcription:

Reference #: MC/M020 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan (PCHP) PreferredOne Insurance Company (PIC) Individual PreferredOne Insurance Company (PIC) Large Group PreferredOne Insurance Company (PIC) Small Group Please refer to the member s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member s benefit plan or certificate of coverage, the terms of the member s benefit plan document will govern. Benefits must be available for health care services. Health care services must be ordered by a physician, physician assistant, or nurse practitioner. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration. PURPOSE: The intent of this criteria document is to ensure care is medically necessary. GUIDELINES: Medical Necessity Criteria - must have: I, and any of II-IV I. Member is at least age 2 and younger than age 18. II. Initial treatment must have all of the following: A D A. Confirmed diagnosis from the DSM autism spectrum disorder; and B. is ordered by a physician, physician assistant, nurse practitioner, or licensed mental health provider with expertise in child development; and C. is supervised by a provider, with expertise and training in autism and child development and who is a licensed physician, advanced practice nurse, or a mental health professional, and is practicing within the scope of the provider s professional license. D. Proposed services are based on a comprehensive individualized treatment plan (ITP) that includes documentation of all of the following: 1-7 1. strategies for behavioral change and management of associated symptoms such as aggression or self injury, sleep problems, activity level, and safety; and 2. Persons responsible for each behavioral change strategy, including collaborating applied behavioral therapist, language therapist and allied therapists responsible for specific aspects of behavioral change and development progression. Strategies involve parents as well as school personnel, when appropriate; and

Reference #: MC/M020 Page 2 of 5 3. Measurable, functional goals with timeframes that are clearly defined, directly observed, and continually measured; and 4. An expectation of improvement within a clinically reasonable time frame that is due to the treatment rendered, and not what would be expected in the usual growth and development for the individual if no treatment was provided; and 5. Projected timeframes for care with clear criteria for discharge from services; and 6. Plan for transitioning care from the licensed provider when treatment plan goals are met; and 7. Where applicable, previous and current therapy treatment plans provided by other providers for the purpose of coordinating care and avoiding duplication of services. III. Continued treatment member continues to meet initial treatment criteria must also have documentation of all of the following: A-E A. A progress evaluation is conducted at least every six months by a mental health professional who has expertise in child development and training in autism (formal assessment/standardized testing is done at least yearly) with documented evidence of sustained improvement and progress on stated goals demonstrated by improvement in the targeted abnormal findings, symptoms and/or behaviors of concern measured by the same method used for the initial evaluation; and B. The documented improvement is due to the treatment rendered and not what would be expected in the usual growth and development for the individual if no treatment was provided; and C. Care continues to be medically necessary due to a continued, demonstrated significant delay in function; and D. Appropriate modifications to treatment plan are implemented; and E. Documented plans for tapering and discontinuation of service from the licensed provider(s). [Note: Re-evaluation by the prescribing licensed provider is required every six months. If no or minimal improvement is documented, therapy services are no longer eligible for coverage.] IV. Discharge criteria any of the following: A-D A. is no longer provided by a licensed provider; or B. Ongoing treatment is primarily custodial or maintenance in nature and/or does not require the services of a licensed provider; or C. There is insufficient progress being made to justify further treatment; or D. Member has met the treatment plan goals.

Reference #: MC/M020 Page 3 of 5 EXCLUSIONS: Any of the following: I-V I. Refer to member s benefit plan for specific exclusions. II. Services provided by non-licensed providers. III. Education of non-licensed providers, family and/or school personnel in behavioral change strategies. IV. services that are considered investigative (see Investigative List) A. Auditory Integration Therapy B. Chelation therapy C. Cognitive rehabilitation D. Elimination diets E. Facilitated communication F. Holding therapy G. Hyperbaric Oxygen Therapy H. Immune globulin infusion I. Metallothioneim protein treatment J. Nutritional supplements such as megavitamins, high-dose pyridoxine and magnesium V. Equine/hippotherapy is considered a plan exclusion under Recreational therapy DEFINITIONS: Autism Spectrum Disorder: A range of complex neurodevelopmental disorders, characterized by persistent deficits in social communication and interaction across multiple contexts, restricted repetitive patterns of behavior, interests, or activities, symptoms that are present in the early developmental period, that cause clinically significant impairment in social, occupational, or other important areas of functioning, and are not better explained by intellectual disability or global developmental delay. Such disorders are determined by criteria set forth in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association. Child Development Expertise: Evidence includes, but limited to, board certification/board eligible in developmental and behavioral pediatrics, fellowship/clinical experience, undergraduate focus in neurobiology or behavior, research involvement, professional/specialty society appointment/membership, and relevant published literature. Custodial Care: Services to assist in activities of daily living and personal care that do not seek to cure or do not need to be provided or directed by a skilled medical professional, such as assistance in walking, bathing and feeding. DSM: The most current edition of the American Psychiatric Association Diagnostic and Statistical Manual of Mental Health Disorders. Habilitative Therapy: Therapy provided to develop initial functional levels of movement, strength, daily activity or speech.

Reference #: MC/M020 Page 4 of 5 Homebound: A member is considered homebound if they are unable to leave home without a considerable and taxing effort due to a medical condition. A person may leave home for episodic medical treatment or short, infrequent absences for nonmedical reasons, to attend a funeral, religious service, or graduation; an occasional trip to the barber, a walk around the block; or other infrequent or unique event (eg, a family reunion or other such occurrence.) A member s inability to drive or lack of transportation does not qualify the member for homebound status. Maintenance Care: Care that is not habilitative or rehabilitative therapy and there is a lack of documented significant progress in functional status over a reasonable period of time; performed to maintain clinical status without the ability to expect further clinical improvement, ie, two weeks or more between a therapy session. Rehabilitative Therapy: Therapy provided to restore functional levels of movement, strength, daily activity or speech after a sickness or injury. Training in Autism: Evidence includes, but not limited to, fellowship/clinical experience, educational background focusing on Autism Spectrum Disorders, research involvement, professional/specialty society appointment/membership, and relevant published literature. BACKGROUND: This criteria document is based on expert professional practice guidelines and/or reliable evidence. of autism spectrum disorders requires multidisciplinary management. Optimal treatment and reimbursement is available through a programmatic approach. Home based services are eligible for coverage only if the member is homebound and not an excluded benefit. If services are court ordered see Medical Policy: MP/C001 Court Ordered Mental Health Services. If requesting physical, occupational, or speech therapy services, see medical criteria: MC/N003 Occupational Health and Physical Therapy: Outpatient Setting or MC/N004 Speech Therapy: Outpatient Setting

Reference #: MC/M020 Page 5 of 5 FOR INTERNAL USE ONLY COVERAGE: Prior Authorization: No Coverage is subject to the member s contract benefits. RELATED CRITERIA/POLICIES: Process Manual: UR015 Use of Medical Policy and Criteria Medical Criteria: MC/M024 Autism Spectrum Disorders: Early Intensive Behavioral and Developmental Therapy Medical Criteria: MC/N003 Occupational and Physical Therapy: Outpatient Setting Medical Criteria: MC/N004 Speech Therapy: Outpatient Setting Medical Policy: MP/A004 Autism Spectrum Disorders in Children: Assessment and Evaluation Medical Policy: MP/C001 Court Ordered Mental Health Services. Medical Policy: MP/C009 Coverage Determination Guidelines Medical Policy: MP/I001 Investigative Services REFERENCES: 1. NIH National Institute of Neurological Disorders and Stroke (NINDS); NINDS Asperger Syndrome Information Page, Last Updated June 15, 2011, Accessed September 13, 2011. NINDS Autism Information Page, Last Updated June 15, 2011, Accessed September 13, 2011. Autism Fact Sheet, NINDS, Publication date September 2009 NIH Publication No. 09-1877, Accessed September 13, 2011. NINDS Pervasive Developmental Disorders Information Page, Last Updated June 15, 2011, Accessed September 13, 2011. NINDS Rett Syndrome Information Page, Last Updated June 15, 2011. Accessed September 13, 2011. 2. American Academy of Pediatrics. Sensory integration therapies for children with developmental and behavioral disorders. Pediatrics 2012;129;1186; doi: 10.1542/peds.2012-0876 3. Myers SM, Plauche Johnson C. Management of children with autism spectrum disorders. Pediatrics 2007; 120; 1162. doi: 10.1542/peds.2007-2362. 4. Weissman L, Bridgemohan C. Autism spectrum disorder in children and adolescents: Behavioral and educational interventions. In: UpToDate, Torchia (Ed), UpToDate, Waltham, MA. 2013 5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. 2013. 6. Agency for Healthcare Research and Quality (AHRQ). Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update. Comparative Effectiveness Review Number 137. 7. Minnesota Statute 43A.23 8. Minnesota Statute 62A.3094 9. National Institute of Mental Health. Autism Spectrum Disorder. Retrieved from https://www.nimh.nih.gov/health/publications/autism-spectrum-disorder-qf-15-5511/index.shtml DOCUMENT HISTORY: Created Date: 05/04 Reviewed Date: 11/13/07, 01/08/09, 10/06/09, 09/22/10, 08/31/12, 08/31/13, 08/20/14, 08/20/15, 08/19/16, 11/29/16 Revised Date: 11/08/05, 11/14/06, 09/02/11, 12/07/11, 01/11/12, 11/22/13

PreferredOne Community Health Plan Nondiscrimination Notice PreferredOne Community Health Plan ( PCHP ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PCHP: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Community Health Plan PO Box 59052 Minneapolis, MN 55459-0052 Phone: 1.800.940.5049 (TTY: 763.847.4013) Fax: 763.847.4010 customerservice@preferredone.com You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Language Assistance Services NDR PCHP LV (10/16)

PreferredOne Insurance Company Nondiscrimination Notice PreferredOne Insurance Company ( PIC ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PIC: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Insurance Company PO Box 59212 Minneapolis, MN 55459-0212 Phone: 1.800.940.5049 (TTY: 763.847.4013) Fax: 763.847.4010 customerservice@preferredone.com You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. Language Assistance Services NDR PIC LV (10/16)